Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.947
-0.002 (-0.21%)
Nov 4, 2024, 1:04 PM EST - Market open
Ocugen Employees
Ocugen had 65 employees as of December 31, 2023. The number of employees decreased by 19 or -22.62% compared to the previous year.
Employees
65
Change (1Y)
-19
Growth (1Y)
-22.62%
Revenue / Employee
$111,738
Profits / Employee
-$690,815
Market Cap
272.69M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Zynex | 1,100 |
AngioDynamics | 748 |
AVITA Medical | 207 |
Vanda Pharmaceuticals | 203 |
Fate Therapeutics | 181 |
Heron Therapeutics | 126 |
Atea Pharmaceuticals | 75 |
Inozyme Pharma | 59 |
OCGN News
- 7 days ago - Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 - GlobeNewsWire
- 13 days ago - Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease - GlobeNewsWire
- 18 days ago - Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results - GlobeNewsWire
- 26 days ago - Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial - GlobeNewsWire
- 4 weeks ago - Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa - GlobeNewsWire
- 5 weeks ago - Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference - GlobeNewsWire
- 6 weeks ago - Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm - Business Wire
- 6 weeks ago - Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 - Seeking Alpha